Pharmacological Invivo and invitro potential of resveratrol in experimental rat models of Parkinson’s disease
Objective: Aim of study was to elucidate the pharmacological Invivo and invitro effects and mechanisms of action ofRT in experimental models of PD. Background: The…Establishing and validating 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced zebrafish model of Parkinson’s disease
Objective: The current study aims to establish a zebrafish model of PD using MPTP neurotoxin and the validation of the MPTP effect through swimming behavior…Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)
Objective: To characterize the in vitro and in vivo pharmacologic profile of UCB0022 Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease with reductions in…Long non-coding RNAs in Parkinson’s disease: bringing back life to the grey matter?
Objective: Our study aims to discover and delineate the role of novel long non-coding RNAs (lncRNAs) in Parkinson’s disease (PD). Background: LncRNAs have been widely…Protective mechanism of melatonin via heat shock protein in the MPP+-induced in vitro Parkinson’s disease model
Objective: The objective of this study was to investigate the protective properties of melatonin in an in vitro Parkinson’s disease (PD) model, especially focusing on…Lack of Toll-like receptor 4 is associated with accumulation of alpha-synuclein in the midbrain Parkinson’s disease mice.
Objective: In this study we aimed to investigate the potential role of Toll-like receptor 4 (TLR4) in mediating both the dopaminergic neuron loss and alpha-synuclein (alpha-SYN)…SCFAs participate in the pathogenesis of Parkinson’s disease by regulating NLRP3 inflammasomes activation
Objective: To explore the role and related mechanism of gut microbiota metabolites short-chain fatty acids(SCFAs) in the pathogenesis of Parkinson's disease(PD). Background: Growing research have…Pharmacological activation of Rev-erbα Provides Neuroprotection against Parkinson’s Disease
Objective: In this study, we investigated the effects of SR9009, a Rev-ERB agonist, on the dopaminergic system in the MPTP model of PD. Background: Circadian…Effects of fine particulate matter and cigarette smoking on MPTP-induced dopaminergic neuronal cell death: Implication for Parkinson’s disease
Objective: The objective of this study was to determine the potential neurotoxicity of fine particulate matter (FPM) and the neuroprotective properties of nicotine in the pathogenesis…The Role Imposed by The High-Mobility Group Box 1 (HMGB1) Protein in MPTP-Induced Zebrafish Model of Parkinson’s Disease
Objective: This study aims to investigate the role of HMGB1 protein in mediating neuroinflammatory-induced parkinsonian movement disorder of the MPTP-induced zebrafish model of Parkinson's disease…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »